
COPD Studies Brisbane TA
Taringa Brisbane
Do you have COPD? Are current treatments not giving you the relief you need?
You may be eligible for a clinical research study investigating the safety of a potential new treatment designed to target and reduce inflammation in the airways, with the aim to improve breathing, reduce flare-ups and ease daily symptoms.
By joining, you may receive early access to a potential new treatment, receive regular health checks, and help contribute to research that may benefit others living with COPD.
Description
What to expect
Ages
35 to 75 years old
Duration
The study has a duration of approximately 28 weeks and involves 14 clinic visits
Compensation
Participants will be reimbursed up to $3,200
Eligibility Criteria
You may qualify for this study if you:
Other eligibility criteria apply. A member of our team will check if this study is a good fit for you.
Locations
Chronic Obstructive Pulmonary Disease is a chronic lung condition that gradually narrows the airways and makes breathing more difficult. Over time, the lungs become less able to move air in and out, which can make even simple activities, like walking up a hill, doing household tasks, or keeping up with family life, feel much harder than they used to.
Common symptoms include shortness of breath, coughing, wheezing and fatigue. COPD affects over 300 million people globally and can significantly limit daily activities, social interactions, and overall quality of life. Though it develops gradually, its impact can be life changing.
Current COPD treatment aims to relieve symptoms, improve breathing, and prevent flare ups. These include inhalers, medications, pulmonary rehabilitation and in some cases, oxygen therapy.
This study is evaluating an investigational treatment designed to target specific immune pathways involved in airway inflammation. By reducing this inflammation, the treatment may help:
Participants will be randomly assigned to receive either the study medication or a placebo (inactive substance) given as an intravenous (IV) infusion twice, 28 days apart.
You will not know if you are receiving the study medication or placebo. You will have a 2 in 1 chance of receiving the study medication versus placebo.
You will visit the clinic regularly for health assessments, including lung function tests, symptoms check-ins, and general health monitoring. Throughout the study, our professional clinic team will closely monitor your well-being and provide support at every step.
Why join a clinical research study?
Your privacy is important. All personal information will be kept strictly confidential.
Register your interest today.
Apply now
Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.
Momentum Clinical Research AU is a member of the Global Site Holdings Group. Global Site Holdings Pty Limited ACN 668 977 062 trading as Momentum Clinical Research ABN 51 668 977 062 and our related entities (we, us, our), will use the Personal Information you have provided in the above form to review and respond to your enquiry, to contact you about any future trials or studies you may be eligible for, and otherwise in accordance with our Privacy Policy and as required and authorised by law. We may not be able to provide you with a complete response or a response at all to your enquiry if you do not provide the requested information. Our Privacy Policy also contains further information about how we collect, use, store or disclose your Personal Information, how you may seek access and correction of your Personal Information, and how you may make a complaint about a breach of privacy. If you have questions, please contact us at contact@momentumclinicalresearch.com.